Answer
In human cellular assays, upadacitinib hemihydrate preferentially inhibits signalling by JAK1 or JAK1/3, with functional selectivity over cytokine receptors that signal via pairs of JAK2.
Sources for this answer
- RINVOQ 15 mg prolonged-release tabletsAbbVie Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 28Document updated
Sources checked